Cite
HARVARD Citation
Oyama, K. et al. (2022). Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial . European heart journal. pp. 2958-2967. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Oyama, K. et al. (2022). Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial . European heart journal. pp. 2958-2967. [Online].